Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About Quintiles
Highly selective medicines for genomically defined cancers.
Aisling congratulates the management team of Loxo on its recent acquisition by Eli Lilly.
Learn More About Loxo
Developing late-stage neuroscience compounds targeting migraine and psychiatric disorders.
Learn More About Biohaven
Novel treatments for people living with narcolepsy and other central nervous system disorders.
learn moreLearn More About Harmony Biosciences
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About AimmuneAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms
September 12, 2022
• Total capital raised of $330 million since the Company’s launch in 2020 • Financing expands planned usage of Company’s 20 cGMP suites containing multiple 50L, 500L, 1,000L and 5000L…
READ MORE
Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs
August 15, 2022
LONDON and RALEIGH, NC -- August 15, 2022 -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the…
READ MORE
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
August 9, 2022
LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), today announces its top-line Phase 3 ENHANCE-2 (“Ensifentrine as a…
READ MORE